Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: First efficacy results from ABCSG-12 Veröffentlicht vonadmin 27. Juli 2020 Gnant, M, Mlineritsch, B, Schippinger, W, Luschin-Ebengreuth, G, Poestlberger, S, Menzel, C, Jakesz, R, Kubista, E, Marth, C, Greil, R